The inhibitors and regulators of m6A modification regulators have been explored as therapeutic approaches for treating cancer, such as FTO inhibitors (including rhein, R-2HG, IOX3, and FB23) and METTL3/METTL14 inhibitors (3-deazaadenosine) (Zhou et al., 2020). The gene discussed is FTO; the disease is cancer.